– Flagship products Neurophet AQUA and Neurophet SCALE PET both received 510k
– Plans to cooperate with radiology AI solution platform companies to enter the U.S. market
SEOUL, South Korea, May 18, 2023 /PRNewswire/ — Neurophet, an artificial intelligence (AI) solution company for brain disease, announced that the US Food and Drug Administration (FDA) 510(k) has cleared “Neurophet AQUA”.
Neurophet AQUA is a brain MRI analysis software that analyzes brain atrophy observed in neurodegenerative diseases such as Alzheimer’s disease. It can segment and analyze brain images in just five minutes regardless of race, age, or gender.
Last August, Neurophet SCALE PET, brain PET scan analysis software has received 510(k) clearance. Since both of flagship products Neurophet AQUA and Neurophet SCALE PET received 510(k) clearance, it is now available to enter the U.S., the world’s largest medical device market.
Neurophet plans to supply products to the U.S. market through cooperation with companies that provide radiology AI solution platform services. Currently, Neurophet is having a discussion with related companies about supplying Neurophet AQUA.
Neurophet AQUA is expected to play a key role in the diagnosis and prognosis observation of Alzheimer’s disease which has recently attracted attention due to the growth of the market of anti-amyloid antibody drugs for Alzheimer’s disease.
Abnormal brain atrophy is found in brain MRI of most Alzheimer’s disease patients, and it is also found in patients who have received anti-amyloid antibody drugs that remove beta-amyloid proteins accumulated in the cerebral cortex.
Although the cause of brain atrophy caused by Alzheimer’s disease drug is not medically clear, it is important to continuously monitor brain atrophy while taking the drug. Therefore, the demand for Neurophet AQUA that analyzes brain atrophy is expected to increase.
“Since Neurophet AQUA is FDA-cleared, CE-marked and has received medical device approval from Japan, Singapore, and Korea, we plan to supply our product to the global market through active sales activities,” said CEO Jake Junkil Been of Neurophet. “FDA has cleared the technology of Neurophet AQUA to analyze brain MRI, and Neurophet SCALE PET to analyze brain PET scan which determines the prescription for Alzheimer’s disease treatments, it is expected to be used essentially for clinical trials and the prescription of Alzheimer’s disease treatments.”
He added, “Neurophet is strengthening the position to cope with the expansion of the dementia treatment market in the future by presenting our technology that quantifies vascular neuropathology in brain images which can be used to analyze ARIA (Amyloid-Related Imaging Abnormalities), side effect of anti-amyloid antibody drugs for Alzheimer’s disease at European Congress of Radiology 2023 last March.”
The global Alzheimer’s therapeutics market size was valued at USD 4.2 billion in 2022 and is expected to reach USD 15.6 billion by 2030 at a CAGR of 16.2% from 2022 to 2030, according to a report of Grand View Research, Inc.
About Neurophet
Neurophet has specialized in developing solutions for diagnosis support, treatment guides, and treatment devices targeting brain diseases based on cutting-edge artificial intelligence (AI) technology. The company was founded in 2016 by Jake Junkil Been, CEO, and Donghyeon Kim, CTO, who developed the next-generation neuro-navigation system.
Major products include brain MRI analysis software “Neurophet AQUA”, brain PET scan analysis (PET tracer deposition) software “Neurophet SCALE PET”, brain imaging treatment planning software for electric and magnetic brain stimulation “Neurophet tES/TMS LAB”, and cloud-based brain imaging analysis research tool “Neurophet SegPlus”.
Neurophet has set its top priority to helping patients suffering from brain diseases. Based on expertise in neuroscience, Neurophet will continue to challenge and grow to explore the human brain’s health and pioneer solutions for brain diseases with AI technology.